Monoclonal antibodieshave been raised against human heart-and brain-type creatine kinase (CK-MB and CK-BB). We used a low-affinity monoclonal antibody to develop a simple two-step immunoaffinity purification procedure for native CK-MB. Antibodies of higher affinity were used to construct specific two-site immunoradiometric assays for CK-MB and CK-BB. Inthe assay forCK-MB we used an 1251 labeledB subunit-specific antibodywithan immobilized anti-M subunit antibody-adding either simultaneously, for a 1-h assay inwhich between 5 and 1000 ng of CK-MB per milliliter couldbe measured withan intra-assay CV of4% to 20%, or sequentially, fora 2-h magnetic separation assay in which between 0.5 and 1000 ng/mL could be measured with an intra-assay CV of 14 to 19%. Inboth versionsCK-BB up to 100 ng/mL and CK-MM up to5000 ng/mL didnotinterfere. In the assay forCK-BB we used an 1251-labeled,reduced, and alkylated monoclonal antibody specific for the B subunit of CK-BB, and removed bound isoenzyme with a second immobilized monoclonal antibody specific for a different epitope on the B subunit. Total incubation time for this assay was 5 h. Intra-assay CV was 7.5 to 20% between 0.1 and 1000 ng/mL. CK-MB up to 1000 ng/mL and CK-MM up to 100 000 ng/mL did not interfere. Inter-assay CVs in all three assays varied from 9 to 21%.
An exception has been a rapid 2.5-h assay (11), which could not, however, distinguish between CK-MB and CK-BB. We have previously (14) described a two-siteimmunoradiometric assay involving polyclonal antisera to the M and B subunits of CK-MB; although specific for this isoenzyme, the assay was still relatively lengthy and required large quantities of antigen and antisera. In our present work we have tried, first, to develop assays based on monoclonal antibodies that are sensitive and specific forCK-MB and CK-BB and, second,to reduce assay times to clinically practicable values. We have also addressed an additional problem for both radioimmunoassays and "two-site" assays: the difficulty of purifying suitable quantitiesof CK-MB from human heart foruse as a standard and forassessing crossreactivity with CK-BB (15).
For this, we use a low-affinity monoclonal antibody to purify native CK-MB from human heart by immunoaflinity chromatography.
The method is simple and relatively rapid, producing a CK-MB that is homogeneous by sodium dodecyl sulfate electrophoresis on polyacrylainide gel in only two purification steps.
Materials and Methods

Materials
Tris, diethylamine, and bovine serum albumin were purchased from Sigma Chemical Co., Poole, Dorset, U.K. lodogen reagent was from Pierce & Warriner (UK) Ltd., Chester, Cheshire, U.K. All other chemicals were purchased from BDH Chemicals, Poole, Dorset, U.K., and were of "AnalaR"
grade. All radiochemicals were purchased from Amersham International, Amershain, Bucks, U.K. Sepharose activated with CNBr was purchased from Pharmacia, Uppsala, Sweden, and DE-52 anion-exchange resin from either produced by hybridizing CK-BB with CK-MM as described previously (14) or purified from human heart as described below.
Measurement of Enzymes and Protein
We measured CK activity at 23#{176}C by the method of we used in these studies.
Affinity purification of native CK-MB. Human heart tissue was obtained 7.5 h postmortem and stored at -20 #{176}C until use. After thawing slowly overnight at4 #{176}C, the tissue was trimmed of fat and cut into 1-cm cubes. We homogenized these tissues at 4 #{176}C in a Waring Blendor (five 20-s bursts at maximum speed, spaced at 20-sintervals), at two volumes of buffer (Tris HC1, 50 mmol/L, pH 7.5; buffer A) per unit weight of tissue. After centrifuging the homogenate at 32000 x g in an MSE 18 centrifuge at 4#{176}C for20 mm, we filtered the supernate through four layersof muslin,then loaded it onto a 20 x 6 cm column ofDEAE-cellulose at a flowrateof40 mL/h. We eluted the sample with a linear 0 to 400 mmol/L gradient of NaC1 in buffer A (total volume 500 mL, flow rate 95 mL/h). The peak representing CK-MB activity eluted when the saline content of the gradient was about 150 mmol/L; we concentrated this effluent to 25 mL by ultrafiltration.
We further purified the samples by immunoaffinity with a low-affinity anti-M subunit monoclonal antibody (15AB3; seeTable 1). We had purified thisantibodyfrom ascites fluid as described above and covalently coupled it to CNBractivated Sepharose, following the manufacturer's instructions;the resultingantibody-Sepharose conjugate containedapproximately15 mg ofproteinper gram of Sepharose. We packed 2 gof this slurry into a lOx 2cm column, to a total volume of 10 mL and stored it at 4 #{176}C in sodium phosphate buffer (50 mmol/L, pH 7.5) containing 1 g of sodium azide per liter. Inunediately before use we re- Table 1 . Properties of the Monoclonal Antibodies equilibrated the column with 10 column volumes of a Tris HC1 buffer (50 mmolJL, pH 7.5) containing 500 mmol of NaC1 and 0.1 mmol of 2-mercaptoethanol per liter (bufferB). The concentrated CK-MB fraction from the ion-exchange column was dialyzed overnight at 4#{176}C against buffer B, then applied to the monoclonal antibody-affinity column at a flow rate of 4 mJJh. We then increased the flow rate to 20 mL/h, washed the column with 10 column volumes of modified buffer B (asabove but containing1 mol ofNaCl per liter), eluted the bound CK-MB with cold freshdiethylamine (50 mmoli'L, pH 11.5), and rapidly neutralized the effluent with Tris HC1 buffer (500 mmol/L, pH 7) containing 100 mmol of2-mercaptoethanol per liter. The peak containing CK-MB activity was concentratedto 2.4 mL in a colloidon bag, dialyzed overnight against bufferA, and stored at 0.8 mg/mL at either4 or -70 #{176}C untiluse.
Assay Procedures
One-step immunoradiometric assay for CK-MB.
An Msubunit specific monoclonal antibody (15CH2; see Table 1 ) was purified as described above and covalently coupled to finely divided aminocellulose We used monoclonal antibody 2AC5 (see Table 1 ), a B subunit-specific antibody, as the labeled antibody in the CK-MB assay, iodinating the purified antibody by the method of Bolton and Hunter (24) , in which N-succinimidyl-3-(4-hy-
propionate is used. Specific activities were about 6000 cpmlng or roughly 0. and 100000 (60-70 ng) cpm of labeled 2AC5 antibody. Let stand for 1 hat room temperature, then wash with 2 mL of cold bufferC (diluted with an equal volume of distilled water) containing 2 mL of Triton X-100 (isooctylphenoxypolyethoxyethanol) per liter. Centrifuge (2400 rpm, 4#{176}C, 5 mm), decant the supernate, and wash the pellet again, as above. Count the radioactivity of the reprecipitated pellet for 5 mm (we used an NE1600 gamma counter with a counting efficiency of approximately 75%).
Two-step
assay for CK-MB with a magnitizable solid phase.
Alternatively, one can measure CK-MB with a sequential, rather than simultaneous, addition of antibody reagents. Because thisassay involves extra steps for washing and precipitation, we used a magnetic separation technique rather than centrifugation.
After activation with CNBr (25),the solid phase, cellulose-coated ferrous oxide particles (26), was covalently coupled to purified monoclonal antibody 15CH2 (60 g of antibody per milligram of cellulose), then storedas a 5 mg/mL suspension in buffer C at 4#{176}C.
The assayisperformed as follows. Add 50 L of magnetizable solid-phase to 0.1 mL of eitherstandard or unknown CK-MB solution in 4-mL flat-bottomed plastic tubes (Sarstedt Ltd.), securely held in a metal rack. Incubate with shaking for 1 h at room temperature, then add 1 mL of cold half-strength buffer C containing 2 mL of Triton X-lOO per liter, and rapidly separate the bound from free isoenzyme by sliding the tube track into a magnetic separator so that each tube is positioned over a cobalt-samarium magnet (26). After 3 mm for precipitation, decant the supernates. Remove the rack from the magnetic separator and add 0.1 mL of iodinated 2AC5 antibody in buffer C (about 30000 cpm) to 'each sample. Incubate for 1 h with constant shaking at room temperature, then repeat the wash and precipitate steps, and count the radioactivity of the tubes' contents. Specific activities were typically 10 000 and 15 000 cpm per nanogram or about 0.5 to 0.7 mol of 'I per mole of antibody. We then reduced this material with dithiothreitol, 2 mmoIJL, and alkylated it with saturated N-ethylmaleimide, all as described previously (28). We stored it at 4#{176}C in a 40 mmol/L potassium phosphate buffer containing 0.5 g of gelatin and 0.1 g of sodium azide per liter. The reduction and alkylation increased the avidity of the monoclonal antibody for CK-BB, as described in detail previously (28).
The assay is as follows: Mix 0.1 mL of buffer C containing 30000 cpm of reduced, alkylated, iodinated antibody with 0.1 mL of standard or unknown.
After 3 h at room temperature add 50 pL of monoclonal 2AC5 solid phase and incubate for a further 2 h. Wash the tubes and centrifuge twice as for the one-step CK-MB assay, and count the radioactivity of the pellets as before.
Precision Studies
We estimated intra-assay variation (CV) from standard curves in which each concentration was determined from the means ± SD of eight replicates (29) . Inter-assay variation was calculated from duplicate determinations of 10 different assays of pooled normal serum containing either high (50 or 100 ng/mL) or low (0.5, 5, or 10 ng/mL) concentrations of isoenzyme.
Results
amide gel electrophoresis (Figure 1 CK-BB (Figure 2) .
lmmunoradiometric Assays for CK-MB
The quickest and simplest CK-MB assay involved the simultaneous addition of antibody reagents. However, preliminary experiments with this procedure showed that relatively low concentrations of CK-BB interfered in the assay by competing with CK-MB for iodinated 2AC5 antibody. To diminish this problem, we increased the concentration of labeled antibody. The resulting assay, which was free from interference from CK-BB up to 100 ng/mL and free from interference by CK-MM up to 5000 ng/mL (Figure 3 gel electrophoresis Left to nght: supemate from 32000 x g centrifugationof crude homogenate; concentratedCK-MB peak after ,on.exchangechromatography;concentrated CK-MB peak after elution from the monoclonal antibody affinity column by duethytamine; purified cK-BB from human brain; purified CK-MM from human skeletal muscle; rnatlcers for relative molecular mass (top to bottom): bovine serum albumin (68 000), ovalbumin (42000), carbonic anhydrase (32 000), soybean tsypsininhibitor (24 000).and lysosyme (18 000)
Purification of Native CK-MB
The immunoaffinity purification of native CK-MB from human heart is summarized in Table 2 . We found it necessary to separate the large excess of CK-MM from CK-MB by ion-exchange chromatography before the affinity step. The concentrated CK-MB peak was then applied to the monoclonal antibody column and washed with a highconcentration salt buffer. All CK activity remained bound to the column, until elution with 50 mmoIJL diethylamine.
The eluting CK-MB peak was homogeneous
by SDS-polyacryl- 10 and 100 ng/mL were 22% and 9.2%, respectively.
Alternatively, the problem of CK-BB interference was overcome by a sequential two-site assay involving a magnetic separation system. This gave a 2-h assay that was more sensitive than the simultaneous system, but similarly free of interference from CK-BB up to 100 ng/mL and CK-MM up to 5000 ng/mL (Figure 4) .The intra-assay CV was 14-19% within the CK-MB range of 0.5 to 1000 ng/mL. Interassay CVs measured at 5 and 100 ng of CK-BB per milliliter, were 21% and 16%, respectively.
Immunoradiometric Assays for CK-BB
A standard curve for the two-site CK-BB assay is shown in Figure 5 . The use of reduced, alkylated 2AB2 tracer increasedassay sensitivity some 10-fold as compared with unreduced antibody (Figure 5 ). This I-labeled reduced and alkylated antibody preparation remained usable for two months. There was no interference from CK-MB up to 1000 ng/mL and interference from CK-MM could not be demon0c0
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.S/1. 5 ). Within the CK-BB range 0.1 to 1000 ng/mL the intra-assay CV was 7.5% to 20%. The interassay CV was 15% at 0.5 ng/mL and 12% at 50 ng/mL.
CK-MB and CK-BB Concentrations in Serum of Normal Persons and a Case of Myocardial Infarction
The concentration of CK-MB and CK-BB in 13 healthy 
Discussion
Injection of creatine kinase isoenzymes into mice resulted in a range of monoclonal antibodies, four of which are described here (Table 1) No monoclonal antibodies were produced that were totally specific for either CK-MM or CK-MB. Antibodies specific for CK-BB (e.g., 2AB2 in Table 1 ) exhibited an increased avidity for CK-BB when reduced. Using antibody A2, another member of the epitope group (28), we have investigated the molecular basis of this effect in detail. The increased avidity appears to be due to cleavage of the heavy-heavy interchain disulfide bonds, imparting greater flexibility to the Fab arms and allowing the formation of a high-avidity cyclic complex containing two antibodies and two CK-BB dimers (28). Similarhigh-avidity cyclic complexesbetween antigensand pairsof antibodies have been described in othersystems(30). We do not yet know whether the epitope on CK-BB recognized by antibodies of the 2AB2 type is buried in CK-MB owing to conformational differences or whether it represents a composite antigemc determinant in a bridge region between two B subunitsand can therefore only be present on CK-BB. Antibodies that react with CK-MB and CK-BB (e.g., 2AC5, Table 1 ) recognized a different epitope on the B subunit and did not show an enhanced avidity with mercaptans (unpublished observations).
Monoclonal antibodies recognizing
CK-MB and CK-MM (e.g., 15AB3 and 15CH2, Table 1 ) bound to separate epitopes on the M subunit.Antibody 15CH2 showed no enhancement with mercaptans whilst antibody 15AB3 showed a five-to sixfold increase in apparent affinity for CK-MM when reduced (unpublished observations).
In general, CK isoenzymes appeared to be poorly antigenic in mice and resulted in low serum titres before fusions (unpublished observations).
We chose a low-affinity monoclonal antibody (15AB3 ,  Table 1 Table 2 ). The specific activity of the final product (Table 2) was higher than in our previous procedure (14) but lower than in some reports by other workers (15), possibly due to the longer postmortem age of the heart tissue used as starting material.
CK-MB prepared from human heart appeared to behave identically in the two-site CK-MB assay compared to CK-MB prepared by hybridization (Figure 4) .
The requirements for the use of labeled monoclonal antibodies in immunoassays have been discussed elsewhere. In general, rapid assays require a high-affinity labeled antibody and a high-capacity solid phase (33). The affinity of the latter antibody is less critical, because this can be added in large molar excess (33). Thus, with the CK-MB assays described here the highest affinity anti-B subunit monoclonal antibody available (2AC5, Table 1 ) was chosen as the label and 15CH2 (Table 1) as the solid-phase immunoadsorbent. An additional reason for choosing this combination was that normally the concentration of CK-MM in serum appears to be considerably higher than that of CK-MB or CK-BB (34). Hence, an assay in which the anti-M-subunit antibody was labeled would suffer interference from CK-MM. We used approximately 17 to 25 pg of 15CH2 antibody per tube, which was adequate for measuring CK-MB in the presence of up to 5000 nglmL CK-MM ( Figure  3) . The amounts of labeled anti-B subunit antibody 2AC5 added to the one-step assay sufficed to ensure that up to 100 ng of CK-BB per milliliter did not interfere (Figure 3) . The amount of 2AC5 needed for this (60-70 ng) was such that it was more practicable to dilute the labeled antibody with unlabeled 2AC5 antibody than to add large amounts of radioactivity.
This decreased assay sensitivity.
Although 1 ng of CK-MB per milliliter could be detected with the assay, acceptable precision (intra-assay CV <20%) was only ohmined above 5 ng/mL (Figure 3) . However, this was more than adequate to detect the increased CK-MB concentrations seen in myocardial infarction ( Figure 6 ). Our alternative approach was to develop a two-step assay in which binding of labeled 2AC5 monoclonal antibody by CK-BB could be avoided by removing CK-MB from solution onto a solid phase before adding the tracer. This allowed use of a smaller total amount of higher specific activity 2AC5 antibody with a corresponding improvement in sensitivity (Figure 4 ). This more sensitive form of the assay was also unaffected by CK-MM up to 5000 ng/mL and CK-BB up to 100 ng/mL (Figure 4) . A disadvantage of such an approach was the inconvenience produced by the extra washing steps; however, this was minimized by the use of a magnetic separation procedure (25). This proved to be simple and reproducible if the magnetic particles were shaken in flatbottomed test tubes during the assay; otherwise, sedimentation was too rapid for equilibration to occur (25).
We also describe a rapid labeled-antibody assay for CK-BB in which a labeled monoclonal antibody (2AB2 , Table 1 ) was used, which was virtually specific for CK-BB. The cross reactivity with CK-MB was about 0.1% on a weight basis. At this level it was virtually impossible to exclude the presence of 0.1% CK-BB in the native or hybridized CK-MB preparation. The lack of rise in CK-BB in a patient with a highly increased CK-MB after myocardial infarction (Figure 6) suggests that in practical assay terms the specificity of antibody 2AB2 is essentially absolute.
The use of reduced and alkylated monoclonal antibody 2AB2, which shares the mercaptan enhancement effect with monoclonal antibody A2 (28), results in an increased sensitivity in the assay, which is most marked at lower CK-BB concentrations ( Figure 5 ). The CK-BB assay was unaffected by 1000 ng of CK-MB or 0.1 mg of CK-MM per milliliter. The monoclonal antibody assays described here have overcome most of the difficulties apparent with previous assays (4,5,8-11 ).
CK-MB can be measured specifically in 1 h with a sensitivity adequate to detect myocardial infarction (Figure 6 ) or in 2 h with a sensitivity capable of detecting CK-MB levels in normal subjects (Figure 4) . Assay time for specific measurement of CK-BB in serum has been shortened to 5 h, as compared with several days with previous assays (4, 10) ,and the sensitivity has been improved so that low-normal
CK-BB concentrations can now be detected (Figure5).
With use of monoclonal antibodies, our initial measurements of CK-MB in serum in normal controls show concentrations considerably below those previously determined by us (14) and other workers (11), although the concentrations seen in myocardial infarction ( Figure   6 ) appear to be comparable (11, 14). The reason for this is not yet clear. Similarly, the normal concentration of CK-BB in serum as determined by the two-site monoclonal antibody technique seems lower than that determined by radioimmunoassay (4, 10).Possibly this is because the latter technique recognizes protein fragments that are not detected by the two-site assays. Further work wiil be needed to clarify this point. Another area that can now be examined by using these assays is the extent to which creatine kinase isoenzymes can undergo reversible dissociation in serum or cerebrospinal fluid.
